Skip to main content

Table 1 Demographic and Clinicopathological Characteristics of 74 HCC Patients

From: Targeted blocking of CCR2 and CXCR2 improves the efficacy of transarterial chemoembolization of hepatocarcinoma

Factors

Value

Percent

Age

50.5 ± 12.4

 

Gender (male/female)

67/7

90.5/9.5

BCLC Stage

 A

2

2.7

 B

34

45.9

 C

38

51.4

Types of cirrhosis

 Normal

17

23.3

 Micronodular

4

5.4

 Macronodular

34

45.9

 Mixed

19

25.7

TNM stage

 1

32

43.2

 2

36

48.7

 3

6

8.1

 Neoadjuvant Therapy

0

0

 Hepatectomy

74

100

Laboratory values

 White blood cell (× 109/L)

5.48 ± 1.99

 

 Platelet (× 109/L)

146 ± 73

 

 Total bilirubin (umol/L)

14.6 ± 5.5

 

 Direct bilirubin (umol/L)

5.6 ± 2.7

 

 Albumin (g/L)

42.6 ± 4.1

 

 ALT (U/L)

56.1 ± 40.5

 

 AST (U/L)

42.7 ± 21.4

 

 Glucose (mmol/L)

5.0 ± 1.0

 

 CEA (ng/ml)

4.2 ± 7.9

 

 CA19-9 (U/ml)

14.9 ± 8.5

 

 AFP (ng/ml)

324.7 ± 425.3

 
  1. AFP alpha-fetoprotein, ALT alanine aminotransferase, AST aspartate aminotransferase, BCLC the Barcelona Clinic Liver Cancer, CA19-9 carbohydrate antigen 19–9, CEA Carcinoembryonic antigen, TNM tumor-node-metastasis